The global demand for Pd-L1 Biomarker Testing Market is presumed to reach the market size of nearly USD 15375 MN by 2028 from USD 1613.1 MN in 2021 with a CAGR of 38% under the study period 2022 - 2028.
PD-L1 is a protein whose existence signifies a tumour and surfaces as an early biomarker to be checked in immunotherapy clinical trials. In other words, the protein PD-L1 biomarker testing is used as a brake to check the body's immunological reactions. PD-L1 is probably present on some normal cells and in larger amounts than usual on several cancer cell types. The PD-L1 test calculates how much PD-L1 protein is present in cancer cells.
The PD-L1 Biomarker Testing Market is anticipated to grow rapidly due to rapid technological developments in cancer screening. The growth in the market has also been fueled by the development of cancer immunotherapy, which has enhanced the diagnostic approach to cancer identification and management. However, the difficulties in testing and identifying biomarkers, validating them, and implementing them in molecular diagnostics limit the need for PD-L1 biomarker testing. Nonetheless, PD-L1 biomarker testing is being used for non-small cell lung cancer. Further, it is a useful method for therapeutic usage of PD-L1 proteins for benign lesions or tumour identification. Thus, technological developments in immunotherapy.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pd-l1 biomarker testing. The growth and trends of pd-l1 biomarker testing industry provide a holistic approach to this study.
This section of the pd-l1 biomarker testing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
- PD-L1 IHC 22C3 Assay
- PD-L1 IHC 28-8 Assay
- PD-L1 (SP142) Assay
- PD-L1 (SP263) Assay
- Diagnostic Center
This section covers the regional outlook, which accentuates current and future demand for the Pd-L1 Biomarker Testing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global PD-L1 Biomarker Testing Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the pd-l1 biomarker testing market include Agilent Technologies, Eli Lilly, AstraZeneca, Roche, Bristol-Myers Squibb, Merck, Pfizer. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.